Blue Owl buys Asia-based placement agent
US alternative asset manager Blue Owl Capital has acquired Hong Kong placement agent Ascentium with a view to establishing a physical presence in the territory and pursuing a broader regional expansion.
Financial terms were not disclosed. Ascentium will be renamed Blue Owl Capital HK, and its CEO, James Lee, will serve as head of Blue Owl’s institutional sales team in Asia. It follows closely on the...
Co-Stone leads $43m round for China biosynthesis player
Co-Stone Capital Management has led a CNY 300m (USD 43m) Series B round for Readline, a Shenzhen-based company that specialises in synthetic biology.
Australia’s Heal Partners closes debut fund on $137m
Australia’s Heal Partners, a health, education, and lifestyle-focused venture capital firm, has closed its first fund on AUD 200m (USD 137m). The target was AUD 100m.
US regulator gets access to Chinese audits
The threat of delisting that has haunted Chinese companies that trade on US exchanges appears to have receded after the US regulators announced they had gained full access to the audits of these companies for the first time.